PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
This Quarter Return
+54.17%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$347M
AUM Growth
+$347M
(+61%)
Cap. Flow
+$61.9M
Cap. Flow
% of AUM
17.87%
Top 10 Holdings %
Top 10 Hldgs %
33.52%
Holding
89
New
22
Increased
24
Reduced
19
Closed
10
Top Buys
| 1 |
Humana
HUM
|
$11.6M |
| 2 |
Danaher
DHR
|
$8.84M |
| 3 |
GNMK
GenMark Diagnostics, Inc
GNMK
|
$8.83M |
| 4 |
Edwards Lifesciences
EW
|
$8.29M |
| 5 |
AbbVie
ABBV
|
$7.36M |
Top Sells
| 1 |
Merck
MRK
|
$6.96M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
$6.63M |
| 3 |
Schrodinger
SDGR
|
$5.96M |
| 4 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
$4.77M |
| 5 |
Intuitive Surgical
ISRG
|
$4.49M |
Sector Composition
| 1 | Healthcare | 91.97% |
| 2 | Technology | 0.91% |
| 3 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Neurocrine Biosciences
NBIX
$13.8B
| $14.8M | 4.18% | 121,526 -7,000 | -5% | -$854K |
|
|
GWPH
2
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $14.7M | 4.14% | 119,778 -3,000 | -2% | -$368K |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $14.6M | 4.1% | 261,906 +15,000 | +6% | +$834K |
|
4
DexCom
DXCM
$29.5B
| $13.2M | 3.72% | 32,560 +527 | +2% | +$214K |
|
|
GNMK
5
DELISTED
GenMark Diagnostics, Inc
GNMK
| $11.8M | 3.32% | 800,000 +600,000 | +300% | +$8.83M |
|
|
6
Humana
HUM
$36.5B
| $11.6M | 3.28% | +30,000 | New | +$11.6M |
|
|
7
Merck
MRK
$210B
| $9.73M | 2.74% | 125,826 -90,000 | -42% | -$6.96M |
|
|
8
Danaher
DHR
$147B
| $8.84M | 2.49% | +50,000 | New | +$8.84M |
|
|
AXNX
9
DELISTED
Axonics, Inc. Common Stock
AXNX
| $8.49M | 2.39% | 241,909 | – | – |
|
10
UnitedHealth
UNH
$281B
| $8.41M | 2.37% | 28,500 -6,500 | -19% | -$1.92M |
|
|
11
Edwards Lifesciences
EW
$47.8B
| $8.29M | 2.34% | +120,000 | New | +$8.29M |
|
|
DRNA
12
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $7.64M | 2.15% | 300,805 | – | – |
|
13
Natera
NTRA
$23.1B
| $7.49M | 2.11% | 150,133 +65,000 | +76% | +$3.24M |
|
14
Xenon Pharmaceuticals
XENE
$2.98B
| $7.4M | 2.09% | 590,267 | – | – |
|
|
15
AbbVie
ABBV
$372B
| $7.36M | 2.07% | +75,000 | New | +$7.36M |
|
|
ICAD
16
DELISTED
iCAD Inc
ICAD
| $7.25M | 2.04% | 725,590 | – | – |
|
|
TPTX
17
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $7.13M | 2.01% | 110,318 +30,000 | +37% | +$1.94M |
|
18
Charles River Laboratories
CRL
$8.04B
| $6.97M | 1.96% | +40,000 | New | +$6.97M |
|
|
CTLT
19
DELISTED
CATALENT, INC.
CTLT
| $6.96M | 1.96% | +95,000 | New | +$6.96M |
|
20
IQVIA
IQV
$32.4B
| $6.74M | 1.9% | 47,500 +17,500 | +58% | +$2.48M |
|
21
Vericel Corp
VCEL
$1.83B
| $6.57M | 1.85% | 475,296 +145,000 | +44% | +$2M |
|
22
KORU Medical Systems
KRMD
$195M
| $6.48M | 1.83% | 721,985 +150,000 | +26% | +$1.35M |
|
|
SGEN
23
DELISTED
Seagen Inc. Common Stock
SGEN
| $6.37M | 1.8% | 37,500 +2,390 | +7% | +$406K |
|
24
Mersana Therapeutics
MRSN
$36.5M
| $5.85M | 1.65% | +250,000 | New | +$5.85M |
|
|
25
Vertex Pharmaceuticals
VRTX
$100B
| $5.81M | 1.64% | 20,000 -22,842 | -53% | -$6.63M |
|